Kate Brennan brings 10 years of strategic finance and financial planning and analysis (FP&A) experience spanning both advisory and in-house roles, working with high-growth and well-established organizations across life sciences, healthcare, technology, and financial services, among other industries. She partners with executive teams to build robust operating models and long-range plans that align day-to-day performance with longer-term strategic positioning. She advises C-suite and board-level stakeholders on strategic investment and capital allocation decisions, applying her valuation background to deliver fundraising, M&A, and financial planning analyses.
Kate owns end-to-end budgeting and rolling forecast cycles, working directly with functional leaders on bottom-up financial plans, variance analysis, and multi-scenario three-statement models that stress-test key business assumptions. She builds investment cases that guide resource deployment and corporate strategy, and she delivers rigorous analysis and recommendations to executive stakeholders.
Prior to joining Stout, Kate worked in FP&A at Gerson Lehrman Group, a private equity-backed organization where she led forecasting and consolidated management reporting. Before that, she was a Senior Manager of Strategic Finance at Renalytix, a high-growth biotechnology startup, where she was one of the company’s first employees, reported directly to the CFO, and led modeling and diligence efforts for the company’s Nasdaq IPO. She began her career at Duff & Phelps, performing valuation and financial analysis across M&A, carve-out, and restructuring transactions.
Practice Areas
Education
B.A., Economics, Certificate in Business (Finance Emphasis), University of Wisconsin – Madison
Licenses & Designations
Chartered Financial Analyst (CFA)
Professional Memberships
CFA Institute